Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 50

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 50
---
 Business Units (Specialty Care, General Medicines, Vaccines, and Opella ) as well as the heads of each of the following support functions: Research and Development; Manufacturing & Supply; Finance; People & Culture; Digital, Legal, Business Integrity & Global Security; Corporate Affairs; Ethics and Business Operations. In 2024, we progressed further in building and simplifying our standalone Opella organization. We have further reduced our portfolio, mainly through divestments, to approximately 100 brands (15% fewer than in 2023). In October 2024, in line with our strategy of increased focus on innovative medicines and vaccines, we announced that we had entered into exclusive negotiations with CD&R for the potential sale and purchase of a controlling stake of approximately 50% in Opella. For more information on this potential transaction, see “— B.3 Opella.” Our Corporate Social Responsibility (CSR) strategy aims to build a healthier, more resilient world by ensuring access to healthcare for the world’s poorest people and bringing focus to addressing broader unmet needs. Our commitment to society also aims to accelerate our goal of reducing the environmental impact of our products and of our worldwide operations. Key to tackling the global challenges that face our company are our people, who each have a role to play in building a diverse and inclusive workplace. Our CSR Strategy focuses on four building blocks integrated into our Play to Win core business strategy: • affordable access – to ensure affordable global access to health, while helping healthcare systems to remain sustainable; • R&D for unmet needs – to be at the cutting edge of R&D innovation, to help people live fully and drive growth; • Planet Care – to minimize the environmental impact of our business through environmental sustainability; and • in & beyond the workplace – to give all Sanofi colleagues the chance to become a leader of change, unlocking the potential of our diverse teams. Building on the existing strategy, an evolution of the CSR strategy was presented to and validated by the Board in late 2024. The CSR strategy will be unveiled internally and externally in early 2025 and implemented thereafter. Capital allocation policy We will continue to pursue our focused and disciplined capital allocation policy. Our priorities in deploying the cash generated from our operations are, in the following order: (i) investment in organic growth; (ii) business development and merger & acquisition activities, focusing on bolt-on, value-enhancing opportunities to drive scientific and commercial leadership in core therapeutic areas; (iii) growing the annual dividend; and (iv) anti-d